Castle Biosciences Inc

CSTL

32.750USD

+0.350+1.08%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Castle Biosciences Inc's Score

Industry at a Glance

Industry Ranking

22 / 205

Overall Ranking

102 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Castle Biosciences Inc Highlights

StrengthsRisks

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 142.32% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -79.47, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 26.96M shares, increasing 0.03% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 13.43K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.95.

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

46.286

Target Price

+32.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Castle Biosciences Inc is 6.85, ranking 125 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 83.04M, representing a year-over-year decrease of 3.19%, while its net profit experienced a year-over-year decrease of 122.08%.

Score

Industry at a Glance

Previous score

6.85

Change

0



Financials

9.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.40

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Castle Biosciences Inc is 8.86, ranking 3 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -79.47, which is -296.03% below the recent high of 155.78 and -249.31% above the recent low of -277.59.

Score

Industry at a Glance

Previous score

8.86

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 22/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Castle Biosciences Inc is 9.14, ranking 5 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 37.50, with a high of 45.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

9.14

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Castle Biosciences Inc is 6.62, ranking 114 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 40.81 and the support level at 28.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Castle Biosciences Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 105.78%, representing a quarter-over-quarter decrease of 1.43%. The largest institutional shareholder is The Vanguard, holding a total of 2.19M shares, representing 7.51% of shares outstanding, with 6.17% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.39M

+0.41%

The Vanguard Group, Inc.

Star Investors

2.16M

+0.11%

Principal Global Investors (Equity)

1.79M

-0.26%

Portolan Capital Management, L.L.C.

1.52M

+1.71%

Dimensional Fund Advisors, L.P.

1.47M

+6.97%

Braidwell LP

822.74K

--

Nuveen LLC

770.40K

-0.21%

State Street Investment Management (US)

724.08K

+2.32%

Geode Capital Management, L.L.C.

698.61K

+1.26%

Wasatch Global Investors Inc

Star Investors

669.12K

-36.26%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Castle Biosciences Inc is 7.04, ranking 46 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Castle Biosciences Inc

CSTL

7.90 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Becton Dickinson and Co

BDX

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Align Technology Inc

ALGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment